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Copyright © 2010 by Stéphanie E. B. McArdleThe search for novel tumour antigens that are either uniquely 
expressed or over-expressed in a wide variety of tumours is still 
ongoing. Because of their expression in a broad spectrum of cancers 
and limited expression in normal tissues, cancer/testis antigens are 
considered to be potentially reliable targets for immunotherapy of 
cancer in general. The helicase antigen HAGE has been identified as 
a cancer/testis antigen. However, little is known about its expression 
in normal and cancer tissues. Using a newly developed antibody 
against HAGE, specific staining of its expression by 
immunohistochemistry was validated and optimised on murine 
tumours transfected to express the HAGE protein. The antibody was 
subsequently used to determine HAGE expression in normal human 
and cancer tissue microarrays. HAGE protein expression was 
confirmed in 75% (12/16) of carcinomas as compared to normal 
tissues, which either did not express HAGE at all or expressed HAGE 
at very low levels with the exception of testis. Interestingly, 
discrepancies were also found between mRNA analysis by real time 
quantitative PCR (RT-qPCR) and protein analysis by 
immunohistochemistry, emphasising the need to validate the 
expression of cancer/testis antigens at the protein level prior to the 
development of new vaccine strategies. HAGE is therefore proposed 
to be a valid candidate for designing a broad spectrum vaccine against 
cancer.
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Introduction
There is an ever increasing need for new targets to treat cancer 
considering the limitations of some of the current therapies. It is 
therefore still very important to identify new immunogenic 
tumour-associated antigens (TAAs) that could be potentially 
targeted by immunotherapy in late stage diseases or in 
combination therapy with more traditional treatments at early 
stages to prevent tumour cell proliferation and invasion. The 
helicase antigen, HAGE, might represent such an antigen. It was 
first identified together with sarcoma antigen (SAGE) using 
representational difference analysis in a sarcoma cell line. cDNA 
clones were identified as tumour-specific with a pattern of 
expression very similar to the genes from the MAGE family (1). 
The HAGE gene was mapped to chromosome 6 (6q12-q13) by 
radiation hybrid analysis and encodes a putative 73 kDa protein. 
Analysis of the protein sequence of HAGE revealed that it has a 
DEAD box characteristic of the family of ATP-dependent RNA 
helicases. The sequence also displayed 55% homology with 
DDX5 (p68), another member of this family. RNA metabolism, 
control of cell cycle, spermatogenesis and embryogenesis are 
among the possible processes that HAGE may be involved in. 
However, little is known about its localisation or its precise 
function (1, 2).
Northern blot analysis showed that HAGE transcripts were 
present at a level that was 100-fold higher in a number of 
tumours of varying histological types compared to normal 
tissues, except testis (1). HAGE was later found to be over-
expressed at the mRNA level in a small number of normal 
salivary glands but in a higher proportion in benign and 
malignant salivary gland neoplasms (3). HAGE is also over-
expressed in more than 50% of chronic myeloid leukaemias 
(CMLs), in 20% of acute myeloid leukaemias (AMLs) (4) and 
more than 40% of multiple myelomas (5) and, although HAGE 
is present in a small numbers of lung cancers (1), there is no 
correlation between HAGE gene expression and 
clinicopathological factors, indicating that the detection of 
HAGE in this type of cancer has limited clinical utility (6). More 
recently, we showed that the frequency of HAGE-positive 
individual melanoma tissues reached 50% at the mRNA level, 
although only 20% of samples tested demonstrated a significant 
HAGE expression twice above testis level (7), a result in 
agreement with a previous publication (17%) by Scanlan et al.
(8). We also showed for the first time HAGE expression at the 
protein level in several melanoma cell lines (7). Interestingly, a 
recent study has described the methylation status of the HAGE 
gene in CML patients and cell lines and showed that, like most 
cancer/testis antigens, hypomethylation of the HAGE gene 
promoter correlated with increased HAGE expression and that 
its expression was strongly associated with advanced disease and 
poor prognosis, suggesting a potential role of HAGE in 
increased cellular proliferation and/or survival and as a marker 
of disease progression (9).
Here, we have optimised and validated the specific 
immunohistochemical detection of HAGE at the protein level 
on in vitro and in vivo derived materials using murine tumour 
cells stably transfected to express the HAGE protein. Following 
optimisation, the techniques were applied to multiple normal 
and cancer tissue microarrays. For the first time, HAGE protein 
was detected at different levels in a variety of tumour tissues 
including bladder, brain, breast, colon, esophagus, kidney, liver, 
lung, stomach and small intestine among others, but not in 1 of 8
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HAGE expression in ALC cells determined by RT-qPCR and immunofluorescence. Efficiency of the transfection with the pBudCE4.1/HAGE plasmid was confirmed 
by RT-qPCR (A). Immunofluorescence was observed under a confocal microscope in ALC cells stably transfected with HAGE cDNA (D) but not in ALC cells stably 
transfected with the empty vector (B). No non-specific staining was obtained when ALC/HAGE cells were incubated with rabbit control and secondary antibodies (C). 
HAGE protein expression is mainly localised in the nucleus. Objective magnification: 50x.
Figure 2 
HAGE protein expression in ALC/-Ve and ALC/HAGE tumours determined by immunohistochemical staining. Immunohistochemistry demonstrated the in vivo 
expression of HAGE at the protein level in ALC/HAGE tumours (D), but not in ALC/-Ve tumours (C) excised from DR1/HHDII mice. No non-specific secondary stain-
ing was seen in both ALC/-Ve (A) and ALC/HAGE (B) tumours. HAGE expression was found in the cytoplasm and in the nucleus and appeared to be granular. Objective 
magnification: 20x.
normal tissues or at very low levels with the exception of testis. 
Considering the expression pattern and the diversity of HAGE 
expression in different tumours, HAGE may represent a suitable 
target for immunotherapy.
Results
Analysis of HAGE expression in murine lymphoma and human 
melanoma cell lines
Full length HAGE cDNA was cloned into the pBudCE4.1 
mammalian expression vector. HLA-A2-positive murine 
lymphoma cells (ALC) were grown in a 24-well plate and 
transfected with this plasmid using Lipofectamine 2000 reagent 
as per the manufacturer's instructions. Two days after 
transfection, cells were lysed for RNA extraction and HAGE 
cDNA amplification, or fixed, permeabilised and stained to 
determine HAGE expression by confocal analysis using a 
polyclonal antibody directed against a HAGE-derived peptide 
predicted to be antigenic in silico and produced in rabbits. RT-
qPCR confirmed the expression of HAGE at the mRNA level in 
cells transfected with pBudCE4.1/HAGE but not in cells 
transfected with the empty vector pBudCE4.1/-Ve (Figure 1A). 
Secondary antibody tagged with fluorescein highlights the 
expression and localisation of HAGE within the cells. As can be 
seen from Figure 1, no HAGE protein expression was detected 
in ALC cells transiently transfected with pBudCE4.1/-Ve only, 
whereas cells transfected with pBudCE4.1/HAGE showed a 
significant level of HAGE protein expression ubiquitously found 
in the nucleus of the cells (Figure 1, panels B and D). However, 
ALC/HAGE cells incubated with rabbit control antibody and 
FITC-conjugated goat anti-rabbit antibody showed no staining 
above background (Figure 1C).
Murine lymphoma ALC cells were thereafter stably transfected 
with pBudCE4.1/-Ve or pBudCE4.1/HAGE using 
Lipofectamine 2000 and, following multiple passages in media 
containing the selective antibiotic zeocin, the resulting ALC/-Ve 
and ALC/HAGE cells were used in tumour transplantation 2 of 8 www.cancerimmunity.org
Mathieu et al.Figure 3 
HAGE protein expression in human melanoma cell lines determined by immunofluorescence. Immunofluorescence was observed under a confocal microscope in 
the nucleus of a HAGE-negative FM-3 cell line transfected with HAGE cDNA (FM-3/HAGE) but not in a HAGE-negative FM-3 cell line transfected with an empty plas-
mid (FM-3/Ve). Immunofluorescence was also detected under a confocal microscope predominantly in the nucleus of two HAGE-positive melanoma cell lines, FM-6 
and FM-82. Cells stained with a rabbit isotype control only showed staining from the DRAQ5 compound specific to the nucleus. Objective magnification: 50x.
experiments in HHDII-DR1 double transgenic mice in view of 
developing a tumour model for the design of cancer vaccines 
activating both cytotoxic and helper T cells. After 
determination of the tumorigenic dose rate 50 (TD50; 
6 x 104 cells), ten times the TD50 was used in the in vivo
tumour models. The in vivo expression of HAGE was then 
confirmed by performing immunohistochemistry on excised 
tumours. Whilst no significant staining in ALC/-Ve tumours 
was obtained (Figure 2C), ALC/HAGE tumours showed 
positive staining with the HAGE antibody in a vast majority of 
cells present in the tumour sections (Figure 2D). Sections 
incubated with isotype control did not demonstrate any 
staining above background for both ALC/-Ve and ALC/HAGE 
tumours (Figure 2, panels A and B).
The human melanoma cell line, FM-3, was grown in a 24-well 
plate and stably transfected with either pcDNA3/-Ve or 
pcDNA3/HAGE using Lipofectamine 2000. Stable transfectants 
and two other HAGE-positive melanoma cell lines, FM-6 and 
FM-82, were lysed for RNA extraction and HAGE cDNA 
amplification, or fixed, permeabilised and stained for HAGE 
expression analysis by confocal microscopy using a polyclonal 
anti-HAGE antibody. RT-qPCR confirmed the expression of 
HAGE at the mRNA level in FM-3/HAGE, FM-6 and FM-82 
cells but not in FM-3 cells transfected with the empty vector 
pcDNA3/-Ve (Figure 3A). Secondary antibody tagged with 
fluorescein highlights the expression and localisation of HAGE 
within the cells. As can be seen from Figure 3, no HAGE protein 
expression was detected in FM-3 cells transiently transfected 
with pcDNA3/-Ve only, whereas cells transfected with pcDNA3/
HAGE showed a significant level of HAGE protein expression in 
the nucleus of the cells (Figure 3B). This result was confirmed in 
both HAGE-positive FM-6 and FM-82 cells (Figure 3B). FM-3/
-Ve, FM-3/HAGE, FM-6 and FM-82 cells incubated with rabbit 
control antibody and FITC-conjugated goat anti-rabbit 
antibody showed no staining above background (Figure 3B).
Analysis of HAGE expression in normal tissues
HAGE expression was then assessed in normal human tissues 
using real time quantitative RT-PCR. Primers for HAGE give a 
product size of 220 bp. 2 µg of RNA was used to reverse 
transcribe and generate cDNA using oligo(dT) primers. Real 
time PCR was performed for 40 cycles and relative gene 
expression was derived by calculating the 2δCt values using 
hypoxanthine guanine phosphoribosyltransferase 1 (HPRT1) as 
the housekeeping gene. As seen in Figure 4, relative HAGE 
expression proved to be undetectable or extremely low in all the 
normal tissues tested (0/19) when compared to placenta and 
testis.
Similarly to the analysis performed on murine cells in vitro and 
ex vivo, the anti-human HAGE polyclonal antibody was then 
applied to multiple normal tissue microarrays (TMAs), which 
were stained for HAGE expression following antigen retrieval, 
antiserum incubation and diaminobenzidine 
tetrahydrochloride (DAB) staining. Sixteen healthy tissues 
coming from two donors were examined. Figure 4 demonstrates 
that whilst no significant (Figure 4, panels A-L) or weak 
(Figure 4, panels M and N) staining of normal tissues was 
observed (2/15), normal testis tissues showed positive staining 
with the antibody in the nucleus of spermatogonia and primary 
spermatocytes of both healthy donors (Figure 5O). No non-
specific staining was obtained when multiple normal TMAs 
were incubated with isotype control and secondary antibody 
(Figure 5P). Therefore, protein expression was shown to 
correlate with the mRNA levels observed earlier by RT-qPCR.
Analysis of HAGE expression in tumour tissues
Previous studies have not only focused on the analysis of 
HAGE gene expression in haematological malignancies but also 
in solid tumours. Indeed, HAGE expression has been 
demonstrated to a lower proportion in brain, colon, lung and 
prostate cancers, among others, at the mRNA level (8). However, 
to the best of our knowledge, the presence of HAGE at the 
protein level in these cancers has never been confirmed. Here, 
immunohistochemistry was performed on multiple cancer 
TMAs in order to determine whether HAGE is also expressed at 
the protein level in a large variety of solid tumours. Of the 16 
different cancer tissues examined, 10 of them demonstrated 
HAGE-positive staining (75%) in at least one patient out of four 
for each of these cancers. Figure 6 shows the in situ expression of 
HAGE in several cancers from different tissues including 
bladder (transitional cell carcinoma) and breast (invasive ductal 
carcinoma) at low protein level; brain (astrocytoma, stage II), 
colon (adenocarcinoma) and lung (small cell carcinoma) at 
intermediate protein level; esophagus (squamous cell www.cancerimmunity.org 3 of 8
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HAGE mRNA expression in human normal tissues determined by RT-qPCR. Real time quantitative PCR analysis was carried out on 20 human normal tissues. Data 
are expressed relative to the mRNA level of normal testis which was arbitrarily set as 1.
Figure 5 
HAGE protein expression in multiple normal tissue microarrays determined by immunohistochemistry. Immunohistochemical staining demonstrated the in vivo
expression of HAGE protein at a high level in testis (O), but not in bladder (A), brain (B), breast (C), colon (D), esophagus (E), heart (F), kidney (G), liver (H), ovaries (I), 
pancreas (J), prostate (K), thymus (L), lung (M) or uterus (N). No non-specific staining with a rabbit isotype control was obtained in normal testis tissues (P). Visible are 
spermatogonia (arrow) and mature sperm cells (star). Objective magnification: 40x (inset 100x).
carcinoma), kidney (clear cell carcinoma), liver (hepatocellular 
carcinoma), small intestine (papillary adenocarcinoma) and 
stomach (adenocarcinoma) at high protein level but not in their 
respective patient-matched normal tissues. In those tissues with 4 of 8 www.cancerimmunity.org
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HAGE protein expression in multiple cancer tissue microarrays and patient-matched normal tissues determined by immunohistochemistry. Immunohistochemi-
cal staining demonstrated the in vivo expression of HAGE protein at a low level in bladder transitional cell carcinoma (A2) and breast invasive ductal carcinoma (B2); at 
an intermediate level in astrocytoma (C2), colon adenocarcinoma (D2) and lung squamous cell carcinoma (E2); at a high level in esophagus small cell carcinoma (F2), 
kidney clear cell carcinoma (G2), hepatocellular carcinoma (H2), small intestine papillary adenocarcinoma (I2) and stomach adenocarcinoma (J2) but not in their 
respective matched normal tissues (A1, B1, C1, D1, E1, F1, G1, H1, I1 and J1). Objective magnification: 40x (inset 100x).
a heterogeneous structure, HAGE expression was 
predominantly located in the glandular epithelium. Also, within 
the same malignant tissue, HAGE protein expression was quite 
heterogeneous and not all malignant acini were positive for 
HAGE. This was true within the same core of tissue and also 
between tissue cores (data not shown). No non-specific staining 
was obtained when multiple cancer TMAs were incubated with 
isotype control and secondary antibody (data not shown). Thus, 
HAGE appears to be expressed at higher levels in tumour cells 
than in normal cells and, in the majority of cancers, HAGE 
protein seems to be located in the cytoplasm when sections 
were examined at higher magnification.
Discussion
In the search for new TAAs which could be used as targets for 
anti-cancer therapies, it is important to assess their expression at 
both the mRNA and protein level, in both normal and cancer 
tissues. HAGE was initially identified by Martelange et al. (1), 
who applied the technique of cDNA subtraction to identify 
novel genes with tumour-specific expression. HAGE mRNA was 
found to be expressed by a wide range of tumour tissues at levels 
at least 100-fold that of normal tissues, with the exception of 
testis where this gene was shown to be highly expressed 
constitutively. Furthermore, expression of this gene could be 
induced with the demethylating agent, 5'-AZAC, a classical 
feature of cancer/testis genes (8). Therefore, the authors 
concluded that this gene is a member of the cancer/testis family 
and, based on its tumour-specific expression, may represent a 
potential target for immunotherapeutic vaccination against 
cancer. However, in previous reports, the expression of HAGE 
was not studied in a variety of normal tissues at the mRNA level 
using a more sensitive approach such as quantitative real time 
RT-PCR. This technique detected HAGE expression at very low 
levels in a wide array of 20 normal tissues including lung, 
prostate, spinal cord, stomach and trachea. Furthermore, HAGE 
expression was demonstrated to be at least 2 to 1,000-fold higher 
in placenta and testis than in any other normal tissue tested, 
hence validating previous studies using Northern blot or 
conventional RT-PCR analyses (1, 4).
However, these data are all restricted to the detection of HAGE 
at the messenger RNA level and discrepancies between mRNA www.cancerimmunity.org 5 of 8
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the varying stability of different mRNA molecules, the 
regulatory process of translation, post-translational 
modifications and proteasomal degradation (10, 11). Therefore, 
to truly evaluate the expression of HAGE in normal and 
malignant tissues, analysis at the protein level was required. 
Using a monospecific and polyclonal antibody generated against 
a HAGE-derived peptide predicted in silico to be antigenic and 
exposed on the surface of the protein to the binding of an 
antibody, immunofluorescence and immunohistochemistry 
were respectively carried out on in vitro and in vivo material, as 
well as multiple normal and cancer TMAs. These results also 
provide further details regarding the protein's cellular and 
subcellular localisation.
We first set out to optimise anti-HAGE antibody 
concentration on HLA-A2-positive murine lymphoma ALC 
cells, which were transfected with HAGE cDNA for the 
development of an in vivo tumour model in HHDII-DR1 mice, 
and on human melanoma cell lines. ALC cells were first 
transiently and then stably transfected with pBudCE4.1/HAGE 
to express the HAGE protein. The in vitro and in vivo expression 
of HAGE was confirmed by immunofluorescence of transiently 
transfected in vitro cultured ALC cells and 
immunohistochemistry of stably transfected ALC/-Ve and ALC/
HAGE cells grown in HHDII-DR1 mice to a size of 1 cm2 before 
excision. Transfection of ALC cells led to a predominant nuclear 
expression of HAGE in vitro and in vivo, with a characteristic 
and weak granular staining in the cytoplasm as shown by 
immunohistochemistry. Interestingly, both ALC/-Ve and ALC/
HAGE cells were injected into HHDII-DR1 mice and the rate of 
growth of ALC/HAGE tumours (mean area of 0.76 cm2
± 0.14 cm2) was significantly (P < 0.05) higher than ALC/-Ve 
tumours (mean area of 0.46 cm2 ± 0.14 cm2) 15 days after 
tumour transplantation. This preliminary result suggests that 
the transfected HAGE gene may be implicated in promoting 
tumour cell proliferation/survival in vivo, a finding that requires 
to be confirmed in a NOD/SCID mouse model. Furthermore, 
HAGE was also detected at both mRNA and protein level in 
HAGE-positive FM-3/HAGE, FM-6 and FM-82 cells but not in 
FM-3/-Ve cells. It is also noteworthy to mention that FM-6 cells 
showed the lowest expression at the protein level, i.e. the lowest 
fluorescence signal amongst all HAGE-positive cell lines in spite 
of expressing HAGE mRNA at a higher level than FM-3/HAGE 
or FM-82 cells, indicating that HAGE protein turnover might be 
shorter in FM-6 cells.
Upon antigen retrieval and application of the same protocol 
used for ALC tumours on paraffin-embedded multiple normal 
human TMAs, antibody staining allowed confirmation of the 
relative non-expression of the HAGE protein in all normal 
tissues tested with the exception of testis. Interestingly, 
immunohistochemistry did not detect HAGE at the protein level 
in normal stomach tissues from patients with gastric 
adenocarcinoma (Figure 6J) despite RT-qPCR detecting HAGE 
mRNA in normal stomach tissues at levels comparable to levels 
in placenta. Although the RNA was from a different source than 
the tissue sections, we believe these results emphasise the need 
to perform protein analysis rather than mRNA analysis in order 
to confirm the actual translation of a TAA mRNA into a protein 
before envisaging the use of such a TAA as a target for 
immunotherapy, as RT-qPCR results alone can be misleading 
(10, 11).
HAGE was previously shown to be over-expressed at the 
mRNA level at varying frequencies in various solid tumours 
such as bladder, brain, breast, colon, esophagus, liver, lung and 
skin (8). Using paraffin-embedded multiple cancer TMAs 
including patient-matched adjacent normal tissues, we extended 
these results to the protein expression of HAGE in various solid 
tumours. Bladder and breast cancer tissues demonstrated low 
staining of HAGE protein. Brain, colon, and lung cancer tissues 
had an intermediate level of staining for HAGE protein. Finally, 
esophagus, kidney, liver, small intestine and stomach cancer 
tissues showed a high level of staining for HAGE protein. 
Expression of HAGE could not be detected in patient-matched 
adjacent normal tissues. It is also worth considering that high 
protein expression is not necessarily a prerequisite for an 
effective anti-tumour CTL-mediated response. p53-specific 
CTLs were previously shown to be able to recognise tumour 
cells expressing moderate or low levels of p53, suggesting that in 
this case the protein turnover is more important for CTL-
mediated killing than the actual steady-state level of expression 
(12).
Cancer/testis antigens represent one of the most promising 
groups of tumour-associated antigens identified to date because 
of their almost unique and specific expression in tumours, and 
are rightly investigated for the development of novel T cell-
based immunotherapeutic strategies. The results of this study 
suggest that HAGE could be exploited as a target for T cell-based 
immunotherapy where the immune response would be 
predominantly directed against tumour cells with no serious 
risk of autoimmune reactions against adjacent healthy cells 
within the same organ. Importantly, the cytoplasmic expression 
of HAGE does not preclude its expression as a potential 
immunogenic HLA-linked peptide on the cell surface (13).
Not all tumour antigens are capable of eliciting specific 
immune responses and the immunogenicity of an antigen would 
be the deciding factor in validating HAGE as a potential 
immunotherapeutic target. As immunogenic MHC class I/II 
derived immunogenic peptides were previously identified (7), 
we would like to propose HAGE as a valid target for 
immunotherapy.
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Materials and methods
Animals
Mouse class I (H-2) and class II (IA/IE) double knockout 
C57BL/6 animals transgenic for human HLA-A2.1/-DR1 
(HHDII-DR1) were received as a generous gift from Dr. F. 
Lemonnier (Institut Pasteur, Paris). Colonies were bred at 
Nottingham Trent University animal house in accordance with 
the UK Home Office Codes of Practice for the housing and care 
of animals.
Cell lines, transfection assays and injection procedures
The HAGE-positive melanoma cell lines, FM-6 and FM-82, 
were cultured in RPMI1640 media supplemented with 10% fetal 
calf serum (FCS) and 5 mM L-glutamine. The pcDNA3 
mammalian expression plasmid incorporating the entire HAGE 
cDNA sequence and an ampicillin/neomycin resistance cassette 
was kindly provided by Prof. Thierry Boon (Ludwig Institute for 
Cancer Research, Belgium). The HAGE-negative melanoma cell 
line, FM-3, was seeded at 6 x 105 cells per well in a 24-well plate 
(Sarstedt). The cells were then transfected overnight using 
Lipofectamine 2000 (Invitrogen) (1.2 µg pcDNA3/-Ve or 1.2 µg 
pcDNA3/HAGE) and then washed with fresh media containing 
500 µg/ml G418 (Cambrex). Stable transfectants were made by 
plating 100 cells per well in 200 µl of selective medium in a 
96-well plate. Upon repeated splitting in 96-well plates in 
selective medium, stable FM-3/-Ve and FM-3/HAGE cells were 
obtained, bulked up and stored in liquid nitrogen until required.
The murine lymphoma cell line ALC/A2 (H-2b) (a generous 
gift from Dr. Constantin Baxevanis, Cancer Immunology and 
Immunotherapy Centre, Athens), which is transgenic for the 
HLA-A2.1 class I molecule, was cultured with RPMI1640 
supplemented with 10% FCS, 5 mM L-glutamine and 500 µg/ml 
G418 (Cambrex) (14). The entire open reading frame of HAGE 
was cloned from the pcDNA3 vector into the HindIII and XbaI 
sites of the pBudCE4.1 mammalian expression vector 
(Invitrogen) containing a zeocin selection marker. Using a 
similar protocol as described above, stable transfectants were 
made with either 1.2 µg pBudCE4.1/-Ve or 1.2 µg pBudCE4.1/
HAGE in selective media containing 50 µg/ml zeocin 
(Invitrogen), bulked up and stored in liquid nitrogen until 
required.
HHDII/DR1 mice were injected with 6 x 105 ALC/A2/-Ve or 
ALC/A2/HAGE cells. Animals were monitored three times a 
week for tumour development and size, and were sacrificed 
when tumours reached a size of 1 cm2 according to the Home 
Office guidelines.
Real time quantitative PCR
Samples of mRNA from normal tissues were purchased from 
Clontech. Reverse transcription using the M-MLV reverse 
transcriptase kit (Promega) was performed with Oligo(dT)15
according to the manufacturer's protocol. Real-time PCR was 
carried out using primers specific for HAGE cDNA according to 
the GenBank entry NM_018665 (HAGE-496 
5'-GGAGATCGGCCATTGATAGA-3', HAGE-716 
5'-GGATTGGGGATAGGTCGTTT-3'; product size 221 bp), for 
40 cycles of 95°C, 64.5°C and 72°C, using a Sybr Green 
Supermix (BioRad) and a hot start procedure in a Rotagene real 
time PCR cycler (Corbett). This pair of primers does not 
hybridise to cDNA encoded by the DDX5 (p68) gene which 
shares 55% homology with the HAGE gene. The PCR product 
was sequenced (Eurofins DNA) and determined to be 100% 
homologous to HAGE cDNA. The HPRT1 gene was used as 
housekeeping gene to calculate the 2δCt values indicative of the 
relative expression of our gene of interest, HAGE, in normal 
human tissues.
Antibodies
Monospecific and polyclonal anti-human HAGE antibody was 
produced by Pacific Immunology (USA) following sequential 
immunisation of rabbits in complete Freund's adjuvant (1x) and www.cancerimmunity.org 7 of 8
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mer coupled to a carrier protein (KLH) via a cysteine that has 
been added to the N-terminal of the peptide and determined to 
be immunogenic by in silico analysis (HAGE 517: C-
LHGDREQRDREKALEN). The chosen peptide had no 
homology with highly homologous proteins such as DDX5. 
Upon serum purification of IgG, this antibody was used in 
immunofluorescence and immunohistochemistry. A rabbit 
polyclonal antibody IgG (Affinity BioReagents, USA) was used 
as an isotype control. Goat anti-rabbit FITC and goat anti-rabbit 
biotin were obtained from Dako (USA).
Immunofluorescence
Murine lymphoma and human melanoma cells were plated in 
an eight-chamber slide (BD Biosciences) at a concentration of 
1 x 104 cells per well. After overnight incubation at 37°C, 5% 
CO2, cells were fixed and permeabilised at room temperature 
using a solution of 1% (w/v) paraformaldehyde (applied for 10 
minutes) and 70% (v/v) ethanol (applied for 10 minutes), 
respectively. Cells were washed and then stained with 4 µg/ml 
HAGE-specific rabbit polyclonal anti-serum and 10 µg/ml 
fluorescein-conjugated goat anti-rabbit Ig with the slides placed 
on ice. After multiple washes in PBS [0.1% (w/v) BSA, 0.02% (w/
v) NaN3], murine lymphoma cells were left to dry at room 
temperature and prepared with fluorescent mounting media 
(Dako). Human melanoma cells were washed in PBS [0.1% (w/
v) BSA, 0.02% (w/v) NaN3]. Their nuclei were stained with 
2.5 mM of the nuclear DNA dye, DRAQ5 (Biostatus Ltd), for 30 
minutes at room temperature (RT) and the cells were then left to 
dry at room temperature and prepared with fluorescent 
mounting media (Dako). Cells were observed by confocal 
microscopy using a Leica TCS-NT microscope and captured 
using Leica TCS-NT software (50x magnification).
Immunohistochemistry
Paraffin-embedded multiple normal and tumour human 
tissue microarrays (TMAs) were purchased from US Biomax 
(USA). Tumours (1 cm2) were excised from HHDII/DR1 mice 
and embedded in OCT media, fixed in a cold solution of 
2-butanol (Sigma) and sectioned using a cryostat CM1900 
(Leica). Prior to immunohistochemistry, antigen retrieval was 
carried out on paraffin-embedded tissues. Briefly, sections were 
de-waxed in xylene and re-hydrated in graded ethanol [100%, 
100% and 70% (v/v)]. Slides were consecutively rinsed in tap 
water and in ddH2O before being heated up in 0.01 M citrate 
buffer pH 6.0 for 10 minutes in the microwave. Following this 
stage, both frozen and paraffin-embedded tissues underwent 
the same protocol. 0.03% (v/v) H202 diluted in 1x PBS was 
added to the tissue sections for 5 minutes before being washed 
with PBS. Sections were then blocked for 10 minutes with 10% 
(v/v) goat serum. Following incubation, the serum was removed 
and 4 µg/ml of rabbit anti-HAGE or rabbit isotype control were 
added for overnight incubation at 4°C. Slides were then washed 
in 1x PBS and 10 µg/ml of biotin-conjugated goat anti-rabbit 
IgG was added. Slides were incubated for 30 minutes at RT and 
washed thoroughly with 1x PBS. The ABC reagent (Vector 
laboratories) was laid onto the slides according to the 
manufacturer's protocol, left to react with secondary antibodies 
for 30 minutes at RT and washed off with PBS. The DAB reagent 
(Vector laboratories) was added to the sections for 10 minutes at 
RT following the manufacturer's instructions in order to react 
with the ABC reagent and was then washed off with ddH2O. 
Finally, frozen and paraffin-embedded sections were 
counterstained in Gill's and Harris' staining solutions, 
respectively, and fixed consecutively in graded ethanol [70%, 
100%, 100% (v/v)] and in xylene. Slides were mounted, air-dried 
and captured using Mirax Scan (Zeiss). Virtual slides were then 
analysed under (40x) and (100x) magnification.
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